Genyous Biomed

Website Links

Description

Jack Troia was a partner at Deloitte & Touche for fourteen years and in public accounting for over twenty-five years. Mr. Troia was a National Director of the Financial Services Practice and responsible for the financial services practices in the local offices of Deloitte & Touche in Washington, DC and Milwaukee, Wisconsin. He has significant experience in accounting and auditing for public and private companies, mergers and acquisitions, initial and secondary public offerings, financial management, and general business matters. Over the years he has worked with a significant number of businesses, especially in all aspects of financial management, business planning, accounting, and information systems.

James Dao is a successful high tech inventor and entrepreneur based in Silicon Valley with over 35 years of experience in managing, inventing, developing, and commercializing advanced technologies and innovative applications.

Mr. Dao has over twenty years of experience in the creation and management of emerging technology and new business development. Mr. Dao began his career as an application engineer at Communication Intelligence Corporation (CIC), a leading developer of pattern recognition technologies. Over a period of 10 years, Mr. Dao became CIC's head of marketing and sales and contributed to the company's successful IPO on Nasdaq. Mr. Dao also served as Senior Director of Business Development for Oracle Corporation where he helped to build strategic alliances to support the company's CRM and e-Business objectives. Mr. Dao also served as Vice President of Business Development at Nokia Inc., where he managed acquisitions and built strategic alliances to support the company's Internet-communications objectives.

Genyous Biomed International (“Genyous”) was founded in 2000 by a group of practical visionaries who seek to significantly improve the methods used to address the growing burden that prostate cancer is placing on society. Genyous is committed to developing an affordable and well-tolerated integrated healthcare solution comprised of early detection and diagnostics coupled with a new class of multivalent pharmaceuticals intended for prevention, early intervention and treatment of heterogeneous prostate disorders including prostatitis, BPH, PIN, HGPIN and prostate cancer.

Genyous Biomed International was founded in 2000 by a group of practical visionaries who seek a different way to address society's growing cancer burden. By creating an integrated solution to prevent, detect and treat cancer in its earliest stages, Genyous expects to improve the quality of life and reduce mortality for the millions of people diagnosed with cancer each year. It is envisioned that the Genyous solution may ultimately reduce the incidence of cancer. Genyous' initial focus is lung cancer (accounting for the most cancer mortality) and prostate cancer.

Products & services

Similar companies nearby